These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28635770)

  • 1. [The resolution of the expert body for the section on demyelinating diseases of the Russian Society of Neurologists and Russian Executive Committee of multiple sclerosis researchers (Kazan, 19 november 2015) on the 'Current principles and optimization of treatment of patients with relapsing-remitting multiple sclerosis with glatiramer acetate'].
    Redaktsiia
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):78-79. PubMed ID: 28635770
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].
    Boyko AN; Alifirova VM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):135-139. PubMed ID: 29265099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. “Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis” by Qizilbash et al.
    Villoro R
    Clin Ther; 2013 Jan; 35(1):94-5. PubMed ID: 23328271
    [No Abstract]   [Full Text] [Related]  

  • 4. Benefit of endermology on indurations and panniculitis/lipoatrophy during relapsing-remitting multiple sclerosis long-term treatment with glatiramer acetate.
    Márquez-Rebollo C; Vergara-Carrasco L; Díaz-Navarro R; Rubio-Fernández D; Francoli-Martínez P; Sánchez-De la Rosa R
    Adv Ther; 2014 Aug; 31(8):904-14. PubMed ID: 25047757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of multiple sclerosis with glatiramer acetate: a new look].
    Boyko AN; Smirnova NF; Shchukin IA; Lasch NY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7. Vyp. 2):56-61. PubMed ID: 34387447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].
    Boyko AN; Lashch NY; Sharanova SN; Zakharova MN; Trifonova OV; Simaniv TO; Lysogorskaya EV; Guryanova OE; Kotov SV; Iakushina TI; Lizhdvoy VY; Belova YA; Khabirov FA; Babicheva NN; Khaibullin TI; Granatov EV; Averyanova LA; Sazonov DV; Odinak MM; Trinitatsky YV; Tsukurova LA; Sergeeva AI; Ivanov RA; Shustova MS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):61-67. PubMed ID: 28139613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
    Ziemssen T; Calabrese P; Penner IK; Apfel R
    J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.
    Lebrun-Frenay C; Moulignier A; Pierrot-Deseilligny C; Benrabah R; Moreau T; Lubetzki C; Monchecourt F;
    J Neurol; 2019 Apr; 266(4):888-901. PubMed ID: 30730008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate.
    Marsters C; Nathoo N; Amatto L; Wong R; Mahmood MN; McCombe JA
    J Neuroimmunol; 2023 Jul; 380():578110. PubMed ID: 37267695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary.
    Fricska-Nagy Z; Füvesi J; Rózsa C; Komoly S; Jakab G; Csépány T; Jobbágy Z; Lencsés G; Vécsei L; Bencsik K
    Mult Scler Relat Disord; 2016 May; 7():26-32. PubMed ID: 27237753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evolving Mechanisms of Action of Glatiramer Acetate.
    Prod'homme T; Zamvil SS
    Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29440323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
    Zivadinov R; Dwyer MG; Ramasamy DP; Davis MD; Steinerman JR; Khan O
    J Neuroimaging; 2015; 25(6):989-95. PubMed ID: 26394270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients.
    Schreiber H; Hipp J; Roßnagel F; Moritz C
    Neurodegener Dis Manag; 2023 Oct; 13(5):281-288. PubMed ID: 37909320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis.
    Schipper HM; Arnold D; GrandʼMaison F; Melmed C; Moore F; Levental M; Su H; Constantin M; Stril JL; Godin J
    Clin Neuropharmacol; 2015; 38(4):127-31. PubMed ID: 26166235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.
    Honce JM; Nair KV; Sillau S; Valdez B; Miravalle A; Alvarez E; Schreiner T; Corboy JR; Vollmer TL
    Neurology; 2019 Feb; 92(7):e723-e732. PubMed ID: 30635477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A place of first-line drugs in treatment of multiple sclerosis].
    Kasatkin DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.